| Data |
Ora |
Fonte |
Titolo |
|---|
| 24/2/2025 | 13:43 | EDGAR2 | Form 8-K - Current report |
| 24/2/2025 | 13:30 | BW | PepGen Reports Fourth Quarter and Year-End 2024 Financial.. |
| 24/2/2025 | 13:00 | EDGAR2 | Form 10-K - Annual report [Section 13 and 15(d), not S-K.. |
| 24/2/2025 | 13:00 | BW | PepGen Announces Positive Initial Results, Including Robust.. |
| 29/1/2025 | 22:19 | EDGAR2 | Form 8-K - Current report |
| 29/1/2025 | 22:05 | BW | PepGen Announces CONNECT Program Updates |
| 16/12/2024 | 14:00 | EDGAR2 | Form 8-K - Current report |
| 16/12/2024 | 14:00 | BW | PepGen Announces Clinical Hold in the U.S. on IND.. |
| 21/11/2024 | 22:05 | BW | PepGen Reports Inducement Grant Under Nasdaq Listing Rule.. |
| 07/11/2024 | 14:02 | EDGAR2 | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 07/11/2024 | 14:00 | EDGAR2 | Form 8-K - Current report |
| 07/11/2024 | 14:00 | BW | PepGen Reports Third Quarter 2024 Financial Results and.. |
| 04/11/2024 | 14:00 | BW | PepGen to Participate in Upcoming Investor Conferences |
| 08/10/2024 | 14:27 | EDGAR2 | Form 8-K - Current report |
| 08/10/2024 | 13:00 | BW | PepGen Announces Presentations at the 29th Annual Congress.. |
| 19/9/2024 | 22:30 | EDGAR2 | Form 8-K - Current report |
| 19/9/2024 | 22:30 | BW | PepGen Announces Christopher Ashton, PhD, to Retire from its.. |
| 20/8/2024 | 22:05 | BW | PepGen Reports Inducement Grant under Nasdaq Listing Rule.. |
| 20/8/2024 | 14:10 | EDGAR2 | Form 8-K - Current report |
| 20/8/2024 | 14:00 | BW | PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice.. |
| 08/8/2024 | 14:05 | EDGAR2 | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 08/8/2024 | 14:01 | EDGAR2 | Form 8-K - Current report |
| 08/8/2024 | 14:00 | BW | PepGen Reports Second Quarter 2024 Financial Results and.. |
| 30/7/2024 | 22:55 | EDGAR2 | Form 8-K - Current report |
| 30/7/2024 | 22:02 | BW | PepGen Announces Positive Data from Low-Dose Cohort of.. |
| 26/7/2024 | 22:52 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
| 19/7/2024 | 22:09 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
| 16/7/2024 | 22:46 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
| 09/7/2024 | 06:15 | EDGAR2 | Form EFFECT - Notice of Effectiveness |
| 02/7/2024 | 14:00 | BW | PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio.. |
| 13/6/2024 | 22:46 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
| 11/6/2024 | 14:00 | EDGAR2 | Form 8-K - Current report |
| 11/6/2024 | 13:00 | BW | PepGen Announces Executive Team Promotions |
| 07/6/2024 | 22:12 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
| 05/6/2024 | 22:22 | EDGAR2 | Form 144 - Report of proposed sale of securities |
| 18/5/2024 | 02:51 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
| 17/5/2024 | 22:33 | EDGAR2 | Form 144 - Report of proposed sale of securities |
| 14/5/2024 | 22:05 | EDGAR2 | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 14/5/2024 | 22:02 | GLOBE | PepGen Reports First Quarter 2024 Financial Results and.. |
| 14/5/2024 | 22:01 | EDGAR2 | Form 8-K - Current report |
| 13/3/2024 | 21:05 | GLOBE | PepGen to Participate in Upcoming Investor Conferences |
| 13/3/2024 | 12:00 | GLOBE | PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric.. |
| 06/3/2024 | 22:23 | EDGAR2 | Form 10-K - Annual report [Section 13 and 15(d), not S-K.. |
| 06/3/2024 | 22:01 | GLOBE | PepGen Reports Fourth Quarter and Full Year 2023 Financial.. |
| 06/3/2024 | 22:00 | EDGAR2 | Form 8-K - Current report |
| 04/3/2024 | 13:27 | EDGAR2 | Form 8-K - Current report |
| 04/3/2024 | 13:00 | GLOBE | PepGen Announces Clearance of CTA by UK Medicines &.. |
| 01/3/2024 | 23:49 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
| 01/3/2024 | 23:33 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
| 01/3/2024 | 23:29 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
